Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen

BACKGROUND: Factor XI (FXI) is a promising target for novel anticoagulants because it shows a strong relation to thromboembolic diseases, while fulfilling a mostly supportive role in hemostasis. Anticoagulants targeting FXI could therefore reduce the risk for thrombosis, without increasing the chanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar Barroeta, Awital, Marquart, J. Arnoud, Bakhtiari, Kamran, Meijer, Alexander B., Urbanus, Rolf T., Meijers, Joost C. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
THROMBOSIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795894/
https://www.ncbi.nlm.nih.gov/pubmed/35815349
http://dx.doi.org/10.1111/jth.15815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795894/
https://www.ncbi.nlm.nih.gov/pubmed/35815349
http://dx.doi.org/10.1111/jth.15815

Ejemplares similares